X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2168) 2168
Book Review (401) 401
Book / eBook (173) 173
Publication (132) 132
Magazine Article (8) 8
Book Chapter (5) 5
Newsletter (2) 2
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1950) 1950
humans (1776) 1776
female (1228) 1228
male (999) 999
urinary tract infections - drug therapy (629) 629
middle aged (617) 617
aged (588) 588
adult (517) 517
animals (489) 489
abridged index medicus (380) 380
urology & nephrology (295) 295
urinary tract infections (214) 214
rats (212) 212
pharmacology & pharmacy (195) 195
bladder (191) 191
risk factors (181) 181
child (169) 169
adolescent (168) 168
medicine, general & internal (159) 159
treatment outcome (154) 154
cancer (151) 151
aged, 80 and over (148) 148
urology (148) 148
health aspects (145) 145
anti-infective agents, urinary - adverse effects (144) 144
nitrofurantoin - adverse effects (144) 144
time factors (140) 140
research (138) 138
child, preschool (136) 136
analysis (135) 135
mice (135) 135
care and treatment (133) 133
urinary tract infections - complications (127) 127
urogenital system (126) 126
anti-bacterial agents - adverse effects (124) 124
medicine & public health (119) 119
therapy (118) 118
infections (114) 114
urinary tract (112) 112
infant (111) 111
urinary tract infections - chemically induced (111) 111
toxicology (109) 109
oncology (107) 107
antibiotics (106) 106
urinary bladder (106) 106
dose-response relationship, drug (103) 103
urinary bladder neoplasms - chemically induced (102) 102
urine (100) 100
bladder cancer (98) 98
medicine (98) 98
diagnosis (94) 94
kidney diseases - chemically induced (94) 94
surgery (94) 94
cystitis - chemically induced (92) 92
pregnancy (92) 92
diseases (91) 91
article (88) 88
inflammation (88) 88
double-blind (87) 87
retrospective studies (86) 86
drug therapy (85) 85
microbiology (85) 85
double-blind method (80) 80
drug therapy, combination (78) 78
complications and side effects (77) 77
research article (77) 77
infectious diseases (76) 76
medical research (76) 76
urinary organs (76) 76
disease models, animal (75) 75
urinary bladder - drug effects (75) 75
prospective studies (74) 74
urinary bladder - pathology (74) 74
urologic diseases (74) 74
efficacy (73) 73
follow-up studies (73) 73
urinary incontinence (72) 72
bacterial infections - drug therapy (71) 71
diabetes mellitus, type 2 - drug therapy (71) 71
pediatrics (71) 71
cystitis (69) 69
urinary tract diseases (69) 69
bacteria (68) 68
anti-bacterial agents - therapeutic use (67) 67
anti-infective agents - adverse effects (67) 67
risk (67) 67
administration, oral (66) 66
respiratory tract infections - drug therapy (66) 66
safety (66) 66
diabetes (64) 64
rodents (64) 64
trimethoprim - adverse effects (64) 64
young adult (64) 64
trimethoprim, sulfamethoxazole drug combination - adverse effects (63) 63
urinary bladder neoplasms - pathology (62) 62
urinary tract infections - microbiology (62) 62
clinical trials as topic (61) 61
genitourinary organs (61) 61
immunology (61) 61
recurrence (61) 61
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (147) 147
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Scarborough Hospital - General (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Holland Bloorview Kids Rehabilitation - Stacks (3) 3
Humber River Regional Hospital - Church Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Humber River Regional Hospital - Finch Stacks (2) 2
Providence Healthcare - Reference (2) 2
Scarborough Hospital - Birchmount (2) 2
UofT at Mississauga - Stacks (2) 2
Credit Valley Hospital - Reference (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Law (Bora Laskin) - Stacks (1) 1
Mt Sinai Hospital - Pathology (1) 1
New College (Ivey) - Stacks (1) 1
Online Resources - Online (1) 1
Robarts - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Scarborough - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2159) 2159
German (69) 69
French (47) 47
Japanese (18) 18
Spanish (18) 18
Dutch (9) 9
Italian (9) 9
Russian (7) 7
Swedish (6) 6
Norwegian (5) 5
Polish (5) 5
Czech (4) 4
Finnish (3) 3
Hungarian (2) 2
Danish (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 11, pp. 1100 - 1107
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2014, Volume 16, Issue 2, pp. 124 - 136
AimsDapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), has been shown to improve glycaemic control, stabilize insulin dosing and... 
type 2 diabetes | insulin | inhibitor | SGLT2 | randomized trial | glycaemic control | renal glucose handling | Type 2 diabetes | Randomized trial | Renal glucose handling | Insulin | SGLT2 inhibitor | Glycaemic control | METFORMIN | SELECTIVE SGLT2 INHIBITOR | ADD-ON | MELLITUS | INADEQUATE GLYCEMIC CONTROL | BODY-WEIGHT | PHARMACOKINETICS | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | WEIGHT-GAIN | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Weight Loss - drug effects | Genital Diseases, Female - chemically induced | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Aged, 80 and over | Adult | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Genital Diseases, Male - chemically induced | Insulin - administration & dosage | Treatment Outcome | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Complications and side effects | Glucose metabolism | Care and treatment | Analysis | Urinary tract infections | Glucose | Dextrose | Infections | Diabetes | Index Medicus
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 12/2016, Volume 68, Issue 12, pp. 2867 - 2877
Journal Article
Rheumatology (United Kingdom), ISSN 1462-0324, 03/2017, Volume 56, Issue 3, pp. 378 - 383
Objective. The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with... 
Clinical trials and methods | Infection and arthritis | DMARDs | Rheumatoid arthritis | Biological therapies | biological therapies | MODIFYING ANTIRHEUMATIC DRUGS | TUBERCULOSIS | METHOTREXATE | RISK | RHEUMATOLOGY | rheumatoid arthritis | clinical trials and methods | TRIAL | infection and arthritis | RECOMMENDATIONS | SERIOUS BACTERIAL-INFECTIONS | FACTOR-ALPHA ANTAGONISTS | AGENTS | Intestinal Obstruction - epidemiology | Gastrointestinal Diseases - epidemiology | Humans | Middle Aged | Abscess - epidemiology | Male | Hydroxychloroquine - adverse effects | Intestinal Obstruction - chemically induced | Abscess - chemically induced | Infection - chemically induced | Incidence | Infection - epidemiology | Urinary Tract Infections - chemically induced | Arthritis, Rheumatoid - drug therapy | Pneumonia - chemically induced | Antirheumatic Agents - adverse effects | Respiratory Tract Infections - chemically induced | Adult | Female | Drug Therapy, Combination | Etanercept - adverse effects | Ileus - chemically induced | Pancreatitis - epidemiology | Pneumonia - epidemiology | Linear Models | Pancreatitis - chemically induced | Gastritis - epidemiology | Methotrexate - adverse effects | Urinary Tract Infections - epidemiology | Gastritis - chemically induced | Aged | Respiratory Tract Infections - epidemiology | Sulfasalazine - adverse effects | Gastrointestinal Diseases - chemically induced | Ileus - epidemiology | Index Medicus | Abridged Index Medicus | Clinical Science | 53
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2015, Volume 17, Issue 6, pp. 581 - 590
Aims: To assess the long-term efficacy and tolerability of dapagliflozin versus glipizide as add-on to metformin in patients with inadequately controlled type... 
type 2 diabetes | inhibitor | SGLT2 | dapagliflozin | safety | durability | efficacy | Type 2 diabetes | Durability | Efficacy | Safety | Dapagliflozin | SGLT2 inhibitor | URINARY-TRACT-INFECTIONS | MELLITUS | RANDOMIZED CLINICAL-TRIALS | BODY-WEIGHT | HYPERGLYCEMIA | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | COTRANSPORTER 2 INHIBITOR | PLACEBO-CONTROLLED TRIAL | EMPAGLIFLOZIN | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Double-Blind Method | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Male | Treatment Outcome | Glipizide - therapeutic use | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Drug Therapy, Combination - methods | Glomerular Filtration Rate - drug effects | Urinary Tract Infections - chemically induced | Female | Glucosides - therapeutic use | Aged | Blood Pressure - drug effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Care and treatment | Analysis | Urinary tract infections | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Confidence intervals | Medical research | Diabetes | Diabetes mellitus | Body weight | Blood pressure | Urinary tract | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 12/2016, Volume 118, Issue 12, pp. 1805 - 1811
Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall... 
CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | METAANALYSIS | EFFICACY | REDUCING LIPIDS | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | CARDIOVASCULAR-RISK PATIENTS | OUTCOMES | 9 SERINE-PROTEASE | EZETIMIBE | ATORVASTATIN | Back Pain - chemically induced | Myocardial Infarction - epidemiology | Humans | Middle Aged | Nasopharyngitis - chemically induced | Antibodies, Monoclonal - adverse effects | Coronary Disease - epidemiology | Hypercholesterolemia - drug therapy | Diabetes Mellitus, Type 2 - epidemiology | Clinical Trials, Phase III as Topic | Urinary Tract Infections - chemically induced | Respiratory Tract Infections - chemically induced | Stroke - epidemiology | Pruritus - chemically induced | Hypercholesterolemia - epidemiology | Acute Coronary Syndrome - epidemiology | Comorbidity | Ezetimibe - adverse effects | Angina, Unstable - epidemiology | Influenza, Human - chemically induced | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Clinical Trials, Phase II as Topic | Stroke (Disease) | Medical colleges | Analysis | Low density lipoproteins | Atherosclerosis | Monoclonal antibodies | Health aspects | Coronary heart disease | Antilipemic agents | Studies | Confidence intervals | FDA approval | Diabetes | Pruritus | Drug dosages | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2015, Volume 17, Issue 10, pp. 936 - 948
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2015, Volume 17, Issue 3, pp. 294 - 303
Aims: The long-term efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated over 104 weeks in patients aged 55-80... 
phase | study | type 2 diabetes | inhibitor | SGLT2 | canagliflozin | III | Phase III study | Type 2 diabetes | Canagliflozin | SGLT2 inhibitor | GLYCEMIC CONTROL | PLACEBO | BACKGROUND METFORMIN | ADD-ON | SITAGLIPTIN | MELLITUS | phase III study | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | POOLED ANALYSIS | GLIMEPIRIDE | INHIBITOR | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Male | Osmolar Concentration | Urinary Tract Infections - chemically induced | Aged, 80 and over | Cholesterol, LDL - blood | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Metformin - administration & dosage | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Fasting | Double-Blind Method | Cholesterol, HDL - drug effects | Cholesterol, LDL - drug effects | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Diuresis - drug effects | Cholesterol, HDL - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Mycoses - chemically induced | Glucose metabolism | Low density lipoproteins | Mycoses | Hemoglobin | Urinary tract infections | Blood lipids | Glucose | Dextrose | Medical research | Blood pressure | Diabetes | Cholesterol | Index Medicus
Journal Article